- Orion projects 2025 net sales between €1.55 billion and €1.65 billion; the estimated sales are around €1.6 billion.
- The company expects EBIT (Earnings Before Interest and Taxes) to range from €350 million to €450 million, with an estimated €385.5 million.
- Fourth-quarter earnings per share (EPS) were €0.52, surpassing the estimate of €0.47.
- Fourth-quarter net sales of €434.4 million slightly missed the estimate of €435.2 million.
- Fourth-quarter EBIT was €92.7 million, showing a slight decline of 0.2% year-over-year.
- Pretax profit for the fourth quarter came in at €91.7 million, slightly below the €92.6 million estimate.
- Easyhaler Products revenue reached €46.2 million, an increase of 8.5% year-on-year.
- Nubeqa revenue saw significant growth, climbing to €152.0 million compared to €62.2 million in the previous year.
- Simdax revenue was €5.0 million, reflecting a decrease of 9.1% year-on-year.
- Entacapone products generated €22.5 million in revenue.
- The dividend per share for 2024 was €1.64, slightly below the estimated €1.70.
- CEO Liisa Hurme expressed optimism for future growth in 2025, noting that four out of five business divisions increased their net sales in 2024.
- Current market consensus includes 5 buy ratings, 2 hold ratings, and 1 sell rating.
A look at Orion Oyj Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Orion Oyj, a pharmaceutical and diagnostic kit manufacturer, holds a promising long-term outlook based on its Smartkarma Smart Scores. With a stellar Growth score of 5, the company shows strong potential for future expansion in the industry. Additionally, Orion Oyj demonstrates a high level of Resilience and Momentum, scoring 4 on both factors, indicating its ability to weather market fluctuations and maintain a steady growth trajectory.
Although the Value score is lower at 2, suggesting less attractive pricing metrics, the company’s Dividend score of 3 signifies its commitment to rewarding shareholders. Overall, Orion Oyj‘s impressive scores, particularly in Growth, Resilience, and Momentum, position it well for success in the long run within the pharmaceutical and diagnostic kit market.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
